The following original research abstracts will be presented at the Poster Session:
- De-Risking Clinical Trials Leveraging MRI-Guided Intraparenchymal Delivery by Validating Commercially Available Infusion Pumps for Gene and Cell Therapy Infusions
- Intraparenchymal Infusions to Deep Brain Structures Using Low Field MRI (in collaboration with
The Ohio State University Wexner Medical Center )
Additionally, the Company’s technology will be featured in multiple partner posters and presentations. Conference attendees may visit the
“The ASGCT Annual Meeting provides an extraordinary opportunity for us to connect with our existing partners, and attract potential new customers,” stated
About
Forward-Looking Statements
This press release contains forward-looking statements within the context of the federal securities laws, which may include the Company’s expectations for the future performance, market, and revenue of its products and services. These forward-looking statements are based on management’s current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company’s products and services; the Company’s ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company’s products and services in their delivery of therapies; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company’s ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company’s actual results are described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended
Contact: Media Contact:Jacqueline Keller , Vice President of Marketing (888) 287-9109 ext. 4 info@clearpointneuro.com Investor Relations: Danilo D’Alessandro, Chief Financial Officer (888) 287-9109 ext. 3 ir@clearpointneuro.com
Source:
2024 GlobeNewswire, Inc., source